GeneQuine Adds World Renowned Osteoarthritis Key Opinion Leader Prof. Yves Henrotin to Advisory Board [ 13 Jan 2020 ]

GeneQuine Biotherapeutics, a biotech company developing gene therapy for osteoarthritis and other musculoskeletal disorders, is pleased to name the internationally recognized osteoarthritis key opinion leader Prof. Yves Henrotin as a new member of the advisory board.

GeneQuine Adds World Renowned Osteoarthritis Key Opinion Leader Prof. Yves Henrotin to Advisory Board

Prof. Yves Henrotin is one of the leading international key opinion leaders in the field of osteoarthritis and a renowned expert in low back pain management and research. He is professor of pathology, physical therapy and rehabilitation and director of the bone and cartilage research unit at the University of Liège, Belgium. Furthermore, he was the founder of Artialis SA, Belgium, a company specialized in preclinical and clinical research and development in the field of osteoarthritis and other musculoskeletal disorders. Prof. Henrotin has conducted several osteoarthritis clinical trials and has advised numerous groups on clinical development strategy of osteoarthritis drugs. Prof. Henrotin has published more than 250 scientific peer-reviewed papers and received the “De Cooman” award for his contribution to the better understanding of osteoarthritis pathophysiology. He is a former member of the board of directors of the Osteoarthritis Research Society international (OARSI), the premier organization focused on prevention, diagnosis and treatment of osteoarthritis, and was involved in the development of the OARSI recommendations for non-surgical treatment of osteoarthritis, guidelines for physical function assessment in osteoarthritis patients and recommendations on biomarker application in the development of osteoarthritis drugs. Prof. Henrotin is also vice president of the spine and osteoarthritis sections of the French Society of Rheumatology, and former president of the Belgium Back Society. Prof. Henrotin will advise GeneQuine on the preclinical and clinical development strategy of the company’s lead product candidate GQ-303 for the treatment of osteoarthritis as well as GeneQuine’s new gene therapy program for intervertebral disc degeneration – a major cause for chronic low back pain.

Back